Floatz logo

Bemarituzumab

Endometrial Carcinoma

Centre Leon Berardmonoclonal_antibodyPhase 1/2Active
CC
44/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
29/ 100
Competitive Position
95/ 100

Competitive context

233 Active assets in the Endometrial Carcinoma cohort.

Asset / SponsorPhaseRating
Indocyanine Green
Istanbul University
Phase 4BB
Inno-206
AstraZeneca
Phase 3BB
Olaparib
Qilu Pharmaceutical Co., Ltd.
Phase 4BB
Palbociclib
University Medical Center Groningen
Phase 4BB
FILGRASTIM
Mayo Clinic
Phase 3B

View all 50 →

Same molecule, other indications

Bemarituzumab is also rated in:

renal cell carcinomaDormant
CC
Indicative ·
47 / 100
View asset →
bladder transitional cell carcinomaDormant
CC
Indicative ·
44 / 100
View asset →
cervical cancerDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →